LENZ Therapeutics Inc.
LENZ
Market Cap$708.86M
Close$
$0.88
97.1% downside
Current Fair Value
97.1% downsideOvervalued by 97.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $708.86 Million |
|---|---|
| Enterprise Value | $687.00 Million |
| Dividend Yield | $7.21 (27.9674166020171%) |
| Earnings per Share | $-15.3 |
| Beta | 0 |
| Outstanding Shares | 25,608,594 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.13 |
|---|---|
| PEG | 74.92 |
| Price to Sales | - |
| Price to Book Ratio | 4.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -12.11 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About LENZ Therapeutics Inc.
119 employeesgraphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of...